Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Recor Medical Highlights Paradise uRDN System
Tech medical breakthrough

Recor Medical Highlights Paradise uRDN System

Analysis based on 7 articles · First reported May 15, 2026 · Last updated May 15, 2026

Sentiment
70
Attention
4
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The announcement by Recor Medical regarding its Paradise uRDN system, a new device-based therapy for hypertension, is expected to have a positive impact on the medical device and healthcare industries. This innovation provides a new treatment option for uncontrolled hypertension, potentially increasing revenue for Recor Medical and its parent companies, Cara and Otsuka Pharmaceutical.

Medical Devices Pharmaceuticals Healthcare
Event Summary

Recor Medical, a subsidiary of Cara, marked World Hypertension Day 2026 by highlighting its Paradise uRDN system, an ultrasound-based renal denervation therapy for uncontrolled high blood pressure. This minimally invasive device aims to reduce overactive sympathetic nerve activity, offering a new treatment approach for patients whose hypertension is not adequately managed by lifestyle changes and medication. The Paradise uRDN system has received United States — Food and Drug Administration approval in the United States in November 2023, is CE marked for European Union markets, and has regulatory approval in Japan. Recor Medical is also conducting real-world evidence generation studies in the European Union, the United Kingdom, and the United States to further demonstrate the system's effectiveness.

Key Actions
95 Recor Medical developed system
90 Recor Medical highlights innovation
85 United States — Food and Drug Administration approved system Recor Medical
70 Recor Medical received regulatory approval Japan
60 Recor Medical advancing evidence generation
Entities Involved
priv
Recor Medical
Recor Medical developed the Paradise uRDN system, a device-based therapy for hypertension, and is actively working to expand its access globally. This event highlights their innovation and commitment to addressing uncontrolled hypertension.
Importance 100 Sentiment 75
stock
Otsuka Pharmaceutical
Otsuka Pharmaceutical is the parent company of Cara, which in turn owns Recor Medical. The success and expansion of the Paradise uRDN system could positively impact Otsuka Pharmaceutical.
Importance 60 Sentiment 50
per
Helen Reeve-Stoffer
Helen Reeve-Stoffer, Chief Operating Officer of Recor Medical, emphasized the company's commitment to advancing innovative solutions for hypertension.
Importance 30 Sentiment 0
per
Shon Chakrabarti
Dr. Shon Chakrabarti, Chief Medical Officer of Recor Medical, highlighted the new era in hypertension care with device-based therapies like the Paradise procedure.
Importance 30 Sentiment 0
cnt
United States
The Paradise uRDN system received FDA approval in the United States in November 2023 and is commercially available for patients there.
Importance 20 Sentiment 0
cnt
Japan
The Paradise uRDN system received regulatory approval in Japan.
Importance 20 Sentiment 0
alliance
European Union
The Paradise uRDN system is CE marked and approved in markets where the CE mark is accepted, including the European Union, where Recor Medical is advancing real-world evidence generation through the Global Paradise System Registry.
Importance 20 Sentiment 0
cnt
United Kingdom
Recor Medical is advancing real-world evidence generation through the Global Paradise System Registry in the United Kingdom.
Importance 20 Sentiment 0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration approved the Paradise uRDN system for sale in the United States in November 2023.
Importance 20 Sentiment 0
ngo
World Health Organization
The World Health Organization provides statistics on hypertension, underscoring the global health challenge that Recor Medical's innovation aims to address.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.